Selective activation of TCR-γδ+ cells in endemic Burkitt's lymphoma

Malaria Journal

Table 2 Frequencies (median percentages [95% confidence intervals]*) of activated cells within lymphocyte subsets in Burkitt's lymphoma patients and healthy control donors

Subset		Healthy controls	BL patients	Difference	P(T)*
TCR-αβ^+**	CD25⁺	13.5 [9.3 to 16.9]	8.0 [4.9 to 11.1]	-5.0 [-8.6 to -0.6]	0.04
TCR-αβ⁺	CD69⁺	4.1 [1.2 to 8.5]	2.2 [1.1 to 4.6]	-1.2 [-4.2 to 0.8]	0.20
TCR-αβ⁺	HLA-DR +	12.6 [7.6 to 21.1]	20.2 [11. 4 to 30.0]	7.2 [-0.6 to 16.9]	0.07
TCR-αβ⁺	CD95⁺	36.7 [29.1 to 44.8]	45.4 [16.2 to 58.4]	6.2 [-12.2 to 20.6]	0.40
TCR-γδ⁺	CD25⁺	1.6 [0.9 to 4.6]	5.8 [2.6 to 11. 9]	3.6 [1.0 to 8.1]	0.007
TCR-γδ⁺	CD69⁺	7.5 [2.0 to 14.6]	8.9 [4.0 to 13.3]	1.4 [-4.0 to 8.1]	0.61
TCR-γδ⁺	HLA-DR +	33.3 [16.7 to 50.0]	54.8 [39.6 to 67.8]	22.7 [8.8 to 36.2]	0.003
TCR-γδ⁺	CD95⁺	42.5 [32.5 to 58.3]	68.8 [30.4 to 89.0]	21.3 [-1.7 to 41.0]	0.10

* The statistical significance of differences in medians was calculated by the Mann-Whitney rank-sum test. Confidence intervals for median differences were calculated using CIA 2.0 software [1].
** Defined as CD3⁺ TCR-γδ-negative cells

ISSN: 1475-2875